The Plasma Proteins Market in the United States – 2017 report, published annually since 1977, is a comprehensive market analysis of the therapeutic plasma and recombinant proteins sold in the U.S. in 2017.  It provides sales data and historical trends, in units, dollars and market shares by company.  Regulatory, economic and health care issues affecting the market are also discussed. This report is updated every year.

The report is delivered electronically (Excel and pdf files) and as a hard copy. Individual sections of the report may be purchased separately. For more information or to order this report, please contact The MRB at mrb_ibpn@marketingresearchbureau.com, or call +1 203 799-0298.

 


 

THE PLASMA PROTEINS MARKET
IN THE UNITED STATES — 2017

 

TABLE OF CONTENTS

Page

 

 

1

 

14

15

23

24

42

42

45

45

45

58

59

63

64

65

67

79

88

88

100

125

147

147

147

149

151

154

160

160

165

177

179

187

188

188

189

190

191

191

192

194

200

210

214

216

221

227

240

240

242

245

247

249

257

264

268

272

 

 

 

 

EXECUTIVE SUMMARY

 

1) PLASMA COLLECTIONS

1.1) SOURCE PLASMA COLLECTIONS

1.2) SAFETY MEASURES FOR SOURCE PLASMA

1.3) PLASMA COLLECTION ORGANIZATIONS

2) PLASMA  FRACTIONATION42

2.1) PROCESSING CAPACITY AND THROUGHPUT

2.2) FRACTIONATION PRODUCTION CYCLE

2.3) FRACTIONATION STANDARDS

2.5) PRODUCTION YIELDS

3) MARKET OVERVIEW

3.1) THE PLASMA PROTEINS MARKET BY PRODUCT

3.2) PRICING TRENDS

3.3) PRODUCT MIX

3.4) THE PLASMA PROTEINS MARKET BY COMPANY

3.5) HISTORICAL DEVELOPMENT

3.6) PRODUCT APPROVALS

4) IMMUNE GLOBULIN MARKET

4.1) HYPERIMMUNE GLOBULINS

4.2) POLYVALENT INTRAVENOUS IMMUNE GLOBULIN MARKET (IgG)

5) ALBUMIN MARKET
6) HEMOPHILIA CARE MARKET

6.1) INTRODUCTION

6.2) HISTORICAL DEVELOPMENT

6.3) PATIENT POPULATION

6.4) TREATMENT SUPPORT

6.5) HISTORICAL REVIEW OF COAGULATION FACTORS DEVELOPMENT

6.6) CLINICAL DEVELOPMENTS IN HEMOPHILIA TREATMENTS

6.6.1) Factor

6.7) FACTOR VIII MARKET

6.8) VON WILLEBRAND DISEASE (vWD) MARKET

6.9) FACTOR IX MARKET

6.10) PROTHROMBIN COMPLEX MARKET (PCC)

6.11) INHIBITOR MARKET

6.11.1) Description and Prevalence

6.11.2) Immune Tolerance Induction

6.11.3) Factor By-Passing Agents: FEIBA NF and NovoSeven

6.11.4) Hemlibra

6.11.5) Other Inhibitor Treatments

6.11.5) Market Development

6.12) OTHER BLEEDING DISORDERS

7) ALPHA-1 ANTITRYPSIN MARKET (AAT)
8) C-1 ESTERASE INHIBITOR MARKET (C1-INH)
9) ANTITHROMBIN III (AT III) MARKET
10) FIBRIN SEALANT AND BIOSURGERY MARKETS
11) PROTEIN C
12) DISTRIBUTION OF PLASMA PRODUCTS
13) PROFILES OF THE MAJOR FRACTIONATION COMPANIES

13.1) ADMA BIOLOGICS (formerly BIOTEST PHARMACEUTICALS)

13.2) APTEVO and EMERGENT BIOSOLUTIONS

13.3) BIO PRODUCTS LABORATORY (BPL) Owned by CREAT Group

13.4) BAYER HEALTHCARE

13.5) CSL BEHRING

13.6) GRIFOLS USA

13.7) KEDRION BIOPHARMA

13.8) OCTAPHARMA USA

13.9) SHIRE (formerly Baxter)